The Food and Drugs Authority (FDA) has revoked the Good Manufacturing Practices (GMP) certification of Aveo Pharmaceuticals, an Indian drug manufacturer, over its alleged role in the illegal distribution of opioid-based medications to West Africa. The move follows a BBC Africa Eye investigation, which uncovered how Aveo Pharmaceuticals, through Westfin International, reportedly exported unapproved drugs […]
The FDA has revoked Aveo Pharmaceuticals' GMP certification due to allegations of opioid smuggling. Aveo, an Indian manufacturer, was found to have exported unapproved opioid drugs, containing tapentadol and carisoprodol, to West Africa via Westfin International. In response, the FDA instructed Samos Pharma to terminate its relationship with Aveo and Westfin. Additionally, the registration of six products from Masters Pharmaceutical was suspended. The FDA is enforcing measures against opioid abuse, including seizures, fines, and legal actions, while collaborating with law enforcement to prevent further illicit drug influx.
